ASSESSMENT OF PULMONARY INJURY LEVELS IN COVID-19 PATIENTS CO-INFECTED WITH HIV/AIDS AT THE NATIONAL HOSPITAL FOR TROPICAL DISEASES (1/2022 - 6/2023)
Main Article Content
Abstract
Objectives: To assess the level of lung damage in patients with COVID-19 co-infected HIV/AIDS treated at the National Hospital of Tropical Diseases (NHTD) between January 2022 and June 2023. Subjects and method: A cross-sectional descriptive study was conducted from 01/2022 to 06/2023. Among 97 patients diagnosed with SARS-Cov2 co-infected with HIV/AIDS who met the selection criteria, we assessed clinical dyspnea symptoms, lung damage characteristics, and extent of damage using imaging diagnosis. Results and conclusions: 32/97 (32.9%) patients had clinical symptoms of dyspnea when admitted to the hospital; accompanied by symptoms of cough, fever, rapid breathing, and decreased SPO2 respectively: 90.6%; 87.5%; 84.4%, and 71.9%. Of these, 29/32 (90.6%) cases had to be required with oxygen therapy upon admission to the hospital. Oxygen breathing goggles use a rate of 62.5%. Of these 10/20 (50%) do not meet the requirements to upgrade oxygen support, 1/20 (5%) breathing oxygen masks, and 9/20 (45%) cases must set endotracheal intubation (mechanical ventilation). Out of the total 97 dyspnea patients, 12 had to undergo intubation and mechanical ventilation during the treatment, which accounts for 12.4 percent of the total. Lung damage on CT-Scanner accounted for 54/77 (70.1%) with features of ground glass 70.4%, consolidation 46.3%, and interstitial tissue 24.1%, blurred spots 20.4%, stone paving 9.3%, other lesions 44.4%; damage to both lungs accounts for 83.3%. On chest X-ray, lung damage accounted for 23/28 (82.1%) with ground glass features accounting for 73.9%, consolidation 34.8%, blurred spots 34.8%, tissue interstitial 17.4%, and other lesions 43.5%; damage to both lungs accounted for 87.0%. 100% of patients with severe and critical illness were more likely to have multilobe lung damage than the group of patients with mild and moderate severity, which was statistically significant with p*<0.0001.
Article Details
Keywords
Lung damage, SARS-Cov2, COVID-19, HIV/AIDS.
References

2. Tesoriero JM, Swain CE, Pierce JL, et al. 2021. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open 2021; 4: e2037069.

3. Moradi, Y., Soheili, M., Dehghanbanadaki, H., et al. (2022). The Effect of HIV/AIDS Infection on the Clinical Outcomes of COVID-19: A Meta-Analysis. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 25, 183-192.

4. Kouhpayeh H, Ansari H. (2021). HIV infection and increased risk of COVID-19 mortality: A MetaAnalysis. HIV infection and COVID-19. Eur J Transl Myol 31 (4): 10107, 2021 doi: 10.4081/ ejtm.2021.10107.


5. Mirzaei H, McFarland W, Karamouzian M, et al. 2021. COVID-19 among people living with HIV: a systematic review. AIDS Behav 2021; 25: 85–92.

6. Bộ Y tế. 2018. Hướng dẫn quốc gia xét nghiệm HIV (2018). Ban hành kèm theo Quyết định số 2674/QĐ-BYT, ngày 27 tháng 04 năm 2018 của Bộ trưởng Bộ Y tế.

7. Bertagnolio S, Thwin S S, Silva R, et al. 2022. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV 2022; 9: e486–95. May 10, 2022.

8. Bộ Y tế. (2022), Hướng dẫn chẩn đoán và điều trị COVID-19. Quyết định số 250/QĐ – BYT, ngày 28/01/2022.
